A study recently has proved that stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack. The cells, called cardiosphere-derived stem cells, regrew damaged heart muscles and reversed scarring one year later, the authors say.
Scientist have again achieved a great success by developing a new drug KG5, which kills off cancer and also could wipe out some of the most deadly forms of the disease. It also acts by cutting off the blood supply to tumours.This drug is expected to hit the market in 5years.
Malaria has been a serious issue since a long period of time and controlling malaria has been a top goal of international public-health authorities. Caused by parasites transmitted by infected mosquitoes, malaria annually sickens more than 200 million people and kills nearly 800,000, mostly children in Africa. Because children are the most vulnerable to the disease, efforts to develop a vaccine have focused on them.
The Indian drug industry could make huge gains as over $70 billion worth of drugs are expected to go off patent in the US, the world’s largest pharma market, in the next three years.
The collapse of the property market has left the economy with a huge hole that will be difficult to fill. One of the few sectors that offers hope of growth is the pharmaceutical industry, with senior executives convinced that genuine opportunities remain for Ireland Inc.
Cadila Pharmaceuticals’ plan to indigenously develop Influenza A HINI (swine flu) vaccine in collaboration with US-based Novavax is likely to be delayed as the government has shown caution in giving go-ahead for the clinical trials.
The pharmaceutical market in Russia managed to grow by more than 25% in 2009 despite the economic downturn. But domestic producers are still losing out to their foreign rivals.
Ahmedabad-based Cadila Healthcare Ltd could well be the first Indian company to launch the H1N1 vaccine in India. It expects to bring its vaccine in the market by April 2010.
The government will examine Sun Pharma’s post marketing surveillance studies (PMS) and clinical trials report of breast cancer medicine Letrox (chemical name letrozole) to decide whether the drug should be banned from being marketed, as an anti-infertility drug among young women.
TCG Lifesciences, the Rs 400-crore clinical research organisation (CRO) venture of the Chatterjee Group, has entered into an exclusive collaboration with the US-based pharma giant, Pfizer, to develop a portfolio of pre-clinical molecules for discovery of new drugs.
OncoGenex Pharmaceuticals Inc signed a licensing agreement with Israel's Teva Pharmaceutical Industries Ltd for its cancer therapy for an upfront payment of $60 million, but OncoGenex shares got hammered as investors expected a better deal.
2007 was the year that pharma fell in love with biologics, but as the saying goes, you can't love someone else before you love yourself. 2009 was the year pharma fell in love with itself.
Indian companies engaged in discovery of new drugs have twisted the model as many molecules licensed to foreign collaborators failed to reach the market. This so-called outlicensing strategy has been revised and the domestic companies are conducting a larger part of the initial trials themselves, choosing to license out the molecules much later than they used to.
India's pharmaceutical sector has stepped up its research & development expenditure in a bid to capture a larger market share in highly regulated and emerging markets.
Global multinational drug companies need to outsource manufacturing to low-cost destinations like India has turned out to be a boon for leading drug companies in India such as Ranbaxy, Cipla, Dr Reddy’s Laboratories and Aurobindo.
GE Healthcare announced the launch of FTA DMPK cards for the collection and storage of blood samples for use in pharmacokinetic and toxicokinetic (PK/TK) studies.
Cubist Pharmaceuticals, Inc a leading acute care therapeutics company, announced the signing of a definitive agreement under which Cubist has agreed to acquire privately held Calixa Therapeutics Inc, a biopharmaceutical company focused on the development of novel antibiotics that address the expanding problem of multi-drug resistant Gram-negative pathogens.
Bangalore-based biopharmaceutical start-up Biovel Lifesciences is looking to exit from the life sciences space and is keen for an early outright buyout. Biovel has been in dialogue with several companies including Ranbaxy, Avesthagen, Shantha Biotechnics Ltd and Orchid Chemicals, it is learnt.
Ecron Acunova, a full-service clinical research organization (CRO), with offices across Europe, India and the US, has strengthened its Eastern European presence further by opening a new office in Moscow. Galyna Andriyko will lead the development of the Russian office operations.
Dan Vasella, the chief executive of Swiss firm Novartis, which has been struggling for the last five years to secure the patent rights in India on Glivec, its therapy for a rare form of blood cancer called chronic myeloid leukemia, has spoken again on the alleged gaps in the Indian patent system.